Literature DB >> 24267237

Association between ratio of serum eicosapentaenoic acid to arachidonic acid and risk of cardiovascular disease: the Hisayama Study.

Toshiharu Ninomiya1, Masaharu Nagata, Jun Hata, Yoichiro Hirakawa, Mio Ozawa, Daigo Yoshida, Tomoyuki Ohara, Hiro Kishimoto, Naoko Mukai, Masayo Fukuhara, Takanari Kitazono, Yutaka Kiyohara.   

Abstract

OBJECTIVE: We examined the association between the ratio of serum eicosapentaenoic acid to arachidonic acid (EPA/AA) or the docosahexaenoic acid (DHA)/AA and the development of cardiovascular disease in a general Japanese population.
METHODS: A total of 3103 community-dwelling Japanese individuals aged ≥40 years were followed up for an average of 5.1 years. Serum EPA/AA ratios were categorized into quartiles. The risk estimates were computed using a Cox proportional hazards model.
RESULTS: During the follow-up period, 127 subjects experienced cardiovascular events. Age- and sex-adjusted incidence rates of cardiovascular disease increased with lower serum EPA/AA ratios in individuals with high-sensitivity C-reactive protein (HS-CRP) of ≥1.0 mg/L (p for trend = 0.006), whereas no clear association was observed in those with HS-CRP of <1.0 mg/L (p for trend = 0.27). The multivariable-adjusted risk of cardiovascular disease increased significantly, by 1.52 times (95% confidence interval 1.12-2.04) per 0.20 decrement in serum EPA/AA ratio in subjects with HS-CRP of ≥1.0 mg/L. A lower serum EPA/AA ratio was significantly associated with an increased risk of coronary heart disease, but there was no evidence of an association with stroke. The magnitude of the influence of the serum EPA/AA ratio on the cardiovascular risk increased significantly with elevating HS-CRP levels taken as a continuous variable (p for heterogeneity = 0.007). However, no such association was observed for DHA/AA ratio.
CONCLUSION: Our findings suggest that a lower serum EPA/AA ratio is associated with a greater risk of cardiovascular disease, especially coronary heart disease, among subjects with higher HS-CRP levels in the general Japanese population.
Copyright © 2013 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  AA; CI; Cardiovascular disease; DHA; EPA; Eicosapentaenoic acid; HDL; HR; HS-CRP; High sensitivity C-reactive protein; PUFA; Prospective cohort study; arachidonic acid; confidence interval; docosahexaenoic acid; eicosapentaenoic acid; hazard ratio; high-density lipoprotein; high-sensitivity C-reactive protein; polyunsaturated fatty acid

Mesh:

Substances:

Year:  2013        PMID: 24267237     DOI: 10.1016/j.atherosclerosis.2013.09.023

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  38 in total

1.  Variations in the eicosapentaenoic acid-arachidonic acid ratio associated with age in acute myocardial infarction patients undergoing primary percutaneous coronary intervention.

Authors:  Keisuke Nakabayashi; Kentaro Jujo; Yuho Furuki; Issei Ishida; Hiroshi Ando; Minoru Shimizu; Nobuhisa Hagiwara; Katsumi Saito
Journal:  Heart Vessels       Date:  2018-11-14       Impact factor: 2.037

2.  Whole-blood fatty acids and inflammation in European children: the IDEFICS Study.

Authors:  E M González-Gil; J Santabárbara; A Siani; W Ahrens; I Sioen; G Eiben; K Günther; L Iacoviello; D Molnar; P Risé; P Russo; M Tornaritis; T Veidebaum; C Galli; L A Moreno
Journal:  Eur J Clin Nutr       Date:  2016-01-13       Impact factor: 4.016

3.  Clinical implications of eicosapentaenoic acid/arachidonic acid ratio (EPA/AA) in adult patients with congenital heart disease.

Authors:  Miki Kanoh; Kei Inai; Tokuko Shinohara; Hirofumi Tomimatsu; Toshio Nakanishi
Journal:  Heart Vessels       Date:  2017-07-05       Impact factor: 2.037

4.  Which has the stronger impact on coronary artery disease, eicosapentaenoic acid or docosahexaenoic acid?

Authors:  Koichi Iwamatsu; Shichiro Abe; Hiroaki Nishida; Michiya Kageyama; Takahisa Nasuno; Masashi Sakuma; Shigeru Toyoda; Teruo Inoue
Journal:  Hypertens Res       Date:  2016-01-07       Impact factor: 3.872

5.  Coronary Artery Disease Severity and Cardiovascular Biomarkers in Patients with Peripheral Artery Disease.

Authors:  Hiroyuki Hikita; Takatoshi Shigeta; Shigeki Kimura; Atsushi Takahashi; Mitsuaki Isobe
Journal:  Int J Angiol       Date:  2015-06-26

6.  Low serum docosahexaenoic acid is associated with progression of coronary atherosclerosis in statin-treated patients with diabetes mellitus: results of the treatment with statin on atheroma regression evaluated by intravascular ultrasound with virtual histology (TRUTH) study.

Authors:  Tsuyoshi Nozue; Shingo Yamamoto; Shinichi Tohyama; Kazuki Fukui; Shigeo Umezawa; Yuko Onishi; Tomoyuki Kunishima; Akira Sato; Toshihiro Nozato; Shogo Miyake; Youichi Takeyama; Yoshihiro Morino; Takao Yamauchi; Toshiya Muramatsu; Kiyoshi Hibi; Mitsuyasu Terashima; Ichiro Michishita
Journal:  Cardiovasc Diabetol       Date:  2014-01-13       Impact factor: 9.951

7.  Eicosapentaenoic acid/arachidonic acid ratio and smoking status in elderly patients with type 2 diabetes mellitus.

Authors:  Kenta Okada; Kazuhiko Kotani; Hiroaki Yagyu; Shun Ishibashi
Journal:  Diabetol Metab Syndr       Date:  2014-08-13       Impact factor: 3.320

8.  Importance of fatty acid compositions in patients with peripheral arterial disease.

Authors:  Milan Gautam; Atsushi Izawa; Yuji Shiba; Hirohiko Motoki; Takahiro Takeuchi; Ayako Okada; Takeshi Tomita; Yusuke Miyashita; Jun Koyama; Uichi Ikeda
Journal:  PLoS One       Date:  2014-09-05       Impact factor: 3.240

Review 9.  Omega-3 Fatty Acid Blood Levels Clinical Significance Update.

Authors:  H Robert Superko; Alex R Superko; Gina P Lundberg; Basil Margolis; Brenda C Garrett; Khurram Nasir; Arthur S Agatston
Journal:  Curr Cardiovasc Risk Rep       Date:  2014

10.  The Association between Cerebral White Matter Lesions and Plasma Omega-3 to Omega-6 Polyunsaturated Fatty Acids Ratio to Cognitive Impairment Development.

Authors:  Michihiro Suwa; Shigeru Yamaguchi; Tsuyoshi Komori; Sachiko Kajimoto; Masaya Kino
Journal:  Biomed Res Int       Date:  2015-10-25       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.